No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 114.1x · 10Y median 101.7x · 61st percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:34.791Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Alumis Inc. (ALMS) stock was $6.84 as of Oct 5, 2026, 4:00 PM EDT, down 0.15% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +69.7%
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Biotechnology · South San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.73
Revenue Est.
$1.90M
Last Quarter Results
EPS
$-0.79
vs Estimate
$-0.71
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALMS | $844.28M | $6.84 | -0.15% | +69.72% | N/A | N/A | N/A |
| 2ARDX | $837.43M | $3.39 | +1.50% | -35.42% | +20.95% | -0.20% | vs ALMS |
| 3BBNX | $852.55M | $18.95 | -0.05% | -14.80% | N/A | N/A | vs ALMS |
| 4JBIO | $856.30M | $14.07 | -0.35% | +58.45% | -52.65% | N/A | vs ALMS |
| 5APMD | $866.15M | $21.75 | +1.12% | N/A | N/A | N/A | vs ALMS |
| 6GLUE | $867.60M | $10.27 | -2.19% | +32.51% | -12.32% | N/A | vs ALMS |
N/A
$1.66M
vs Estimate
$3.65M
Consensus Rating
Based on 8 analysts
Average Price Target
$32.13
+369.7% upside
Low
$15.00
Current
$6.84
High
$46.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.82 | $-0.75 | $-0.63 | 4 |
| Quarter ending Dec 2026 | $-0.81 | $-0.73 | $-0.67 | 4 |
| Quarter ending Mar 2027 | $-0.93 | $-0.70 | $-0.47 | 1 |
| Quarter ending Jun 2027 | $-0.92 | $-0.70 | $-0.47 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.48 | $-3.27 | $-3.07 | 6 |
| FY 2027 | $-3.07 | $-2.82 | $-2.60 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.43M | $1.90M | $2.38M | 5 |
| Quarter ending Dec 2026 | $1.43M | $1.90M | $2.38M | 5 |
| Quarter ending Mar 2027 | $562500.00 | $750000.00 | $937500.00 | 4 |
| Quarter ending Jun 2027 | $562500.00 | $750000.00 | $937500.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.30M | $6.40M | $13.00M | 8 |
| FY 2027 | $8.57M | $27.04M | $50.09M | 8 |
